Ceftolozane/tazobactam (CXA 201) for the treatment of intra-abdominal infections

Expert Review of Anti-Infective Therapy

Volumn 12, Issue 11, 2014, Pages 1311-1324

  Maseda, Emilio ^a   Aguilar, Lorenzo ^b   Gimenez, Maria Jose ^b   Gilsanz, Fernando ^a  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^b PRISM AG   (Spain)

Author keywords

AmpC; ceftolozane tazobactam; complicated intra abdominal infections; enterobacteriaceae; extended spectrum b lactamases; Pseudomonas aeruginosa

Indexed keywords

BETA LACTAMASE AMPC; BETA LACTAMASE INHIBITOR; CARBAPENEM; CEFTAZIDIME; CEFTOLOZANE; CEFTOLOZANE PLUS TAZOBACTAM; CEPHALOSPORIN; IMIPENEM; LEVOFLOXACIN; MEROPENEM; METRONIDAZOLE; PIPERACILLIN PLUS TAZOBACTAM; PLACEBO; TAZOBACTAM; ANTIINFECTIVE AGENT; CEPHALOSPORIN DERIVATIVE; DRUG COMBINATION; ENZYME INHIBITOR; PENICILLANIC ACID;

ABDOMINAL INFECTION; ABDOMINAL PAIN; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATE; CLINICAL EFFECTIVENESS; CLOSTRIDIUM DIFFICILE INFECTION; CONCENTRATION RESPONSE; CONSTIPATION; DIARRHEA; DRUG CLEARANCE; DRUG HALF LIFE; DRUG INHIBITION; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG STRUCTURE; EXTENDED SPECTRUM BETA LACTAMASE PRODUCING ENTEROBACTERIACEAE; FEVER; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HEADACHE; HOSPITAL ACQUIRED PNEUMONIA; HUMAN; INJECTION SITE IRRITATION; MAXIMUM PLASMA CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; NAUSEA; NONHUMAN; PARESTHESIA; PERITONITIS; PNEUMONIA; PSEUDOMONAS AERUGINOSA; PYELONEPHRITIS; SINGLE DRUG DOSE; SOMNOLENCE; TIME TO MAXIMUM PLASMA CONCENTRATION; UNSPECIFIED SIDE EFFECT; URINARY TRACT INFECTION; VENTILATOR ASSOCIATED PNEUMONIA; VULVOVAGINITIS; ANALOGS AND DERIVATIVES; DRUG COMBINATION; INTRAABDOMINAL INFECTIONS; MICROBIOLOGY;

ANTI-BACTERIAL AGENTS; BETA-LACTAMASE INHIBITORS; CEPHALOSPORINS; DRUG COMBINATIONS; ENZYME INHIBITORS; HUMANS; INTRAABDOMINAL INFECTIONS; PENICILLANIC ACID;

EID: 84911483559     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/14787210.2014.950230     Document Type: Article

References (95)

1. Solomkin JS, Mazuski JE, Bradley JS, et al. Diagnosis and management of complicated intra-abdominal infection in adults and children: guidelines by the Surgical Infection Society and the Infectious Diseases Society of America. Clin Infect Dis 2010;50:133-64
2. Blot S, De Waele JJ, Vogelaers D. Essentials for selecting antimicrobial therapy for intra-abdominal infections. Drugs 2012;72: e17-32
3. Eckmann C, Dryden M, Montravers P, et al. Antimicrobial treatment of "complicated" intra-abdominal infections and the new IDSA guidelines? A commentary and an alternative European approach according to clinical definitions. Eur J Med Res 2011;16:115-26
4. Vincent JL, Rello J, Marshall J, et al. International study of the prevalence and outcomes of infection in intensive care units. JAMA 2009;302:2323-9
5. Krepel CJ, Gohr CM, Edmiston CE, Condon RE. Surgical sepsis: constancy of antibiotic susceptibility of causative organisms. Surgery 1995;117:505-9
6. Röhrborn A, Wacha H, Schöffel U, et al. Coverage of enterococci in community acquired secondary peritonitis: results of a randomized trial. Surg Infect (Larchmt) 2000;1:95-107
7. Gauzit R, Peán Y, Barth X, Top Study Team. Epidemiology, management, and prognosis of secondary non-postoperative peritonitis: a French prospective observational multicenter study. Surg Infect (Larchmt) 2009;10:119-27
8. Cercenado E, Torroba L, Cantón R, et al. Multicenter study evaluating the role of enterococci in secondary bacterial peritonitis. J Clin Microbiol 2010;48:456-9
9. Sitges-Serra A, López MJ, Girvent M, et al. Postoperative enterococcal infection after treatment of complicated intra-abdominal sepsis. Br J Surg 2002;89:361-7
10. Guirao X. What should and should not be covered in intraabdominal infection. Article in Spanish Enferm Infecc Microbiol Clin 2010;28(Suppl 2):32-41
11. Harbarth S, Uckay I. Are there patients with peritonitis who require empiric therapy for enterococcus? Eur J Clin Microbiol Infect Dis 2004;23:73-7
12. Blot S, De Waele JJ. Critical issues in the clinical management of complicated intra-abdominal infections. Drugs 2005;65: 1611-20
13. Maseda E, Mensa J, Val?á JC, et al. Bugs, hosts and ICU environment: countering pan-resistance in nosocomial microbiota and treating bacterial infections in the critical care setting. Rev Esp Quimioter 2013;26: 312-31
14. Centers for Disease Control and Prevention (CDC). Multidrug-resistant Bacteroides fragilis-Seattle, Washington, 2013. MMWR Morb Mortal Wkly Rep 2013;62: 694-6
15. Nagy E, Urban E, Nord CE; ESCMID Study Group on Antimicrobial Resistance in Anaerobic Bacteria. Antimicrobial susceptibility of Bacteroides fragilis group isolates in Europe: 20 years of experience. Clin Microbiol Infect 2011;17:371-9
16. Frakking FN, Rottier WC, Dorigo-Zetsma JW, et al. Appropriateness of empirical treatment and outcome in bacteremia caused by extended-spectrum-blactamase-producing bacteria. Antimicrob Agents Chemother 2013;57:3092-9
17. Babinchak T, Badal R, Hoban D, et al. Trends in susceptibility of selected Gram-negative bacilli isolated from intra-abdominal infections in North America: SMART 2005-2010. Diagn Microbiol Infect Dis 2013;76:379-81
18. Sheng WH, Badal RE, Hsueh PR; SMART Program. Distribution of extended-spectrum b-lactamases, AmpC b-lactamases, and carbapenemases among Enterobacteriaceae isolates causing intra-abdominal infections in the Asia-Pacific region: results of the study for Monitoring Antimicrobial Resistance Trends (SMART). Antimicrob Agents Chemother 2013;57:2981-8
19. Cantón R, Loza E, Aznar J, et al. Antimicrobial susceptibility of Gram-negative organisms from intraabdominal infections and evolution of isolates with extended spectrum b-lactamases in the SMART study in Spain (2002-2010). Rev Esp Quimioter 2011;24:223-32
20. Paterson DL, Bonomo RA. Extended-spectrum beta-lactamases: a clinical update. Clin Microbiol Rev 2005;18:657-86
21. Rubio-Perez I, Martin-Perez E, Garcia DD, et al. Extended-spectrum beta-lactamase-producing bacteria in a tertiary care hospital in Madrid: epidemiology, risk factors and antimicrobial susceptibility patterns. Emerg Health Threats J 2012;5
22. Dunne WM Jr, Hardin DJ. Use of several inducer and substrate antibiotic combinations in a disk approximation assay format to screen for AmpC induction in patient isolates of Pseudomonas aeruginosa, Enterobacter spp., Citrobacter spp., and Serratia spp. J Clin Microbiol 2005;43:5945-9
23. Livermore DM, Brown DF. Detection of beta-lactamase-mediated resistance. J Antimicrob Chemother 2001;48(Suppl 1): 59-64
24. Hawkey PM. The growing burden of antimicrobial resistance. J Antimicrob Chemother 2008;62(Suppl 1):11-9
25. Miró E, Aguëro J, Larrosa MN, et al. Prevalence and molecular epidemiology of acquired AmpC b-lactamases and carbapenemases in Enterobacteriaceae isolates from 35 hospitals in Spain. Eur J Clin Microbiol Infect Dis 2013;32:253-9
26. Denisuik AJ, Lagacé-Wiens PR, Pitout JD, et al. Molecular epidemiology of extended-spectrum b-lactamase-, AmpC blactamase-and carbapenemase-producing Escherichia coli and Klebsiella pneumoniae isolated from Canadian hospitals over a 5 year period: CANWARD 2007-11. J Antimicrob Chemother 2013;68(Suppl 1):i57-65
27. Cejas D, Fernández Canigia L, Quinteros M, et al. Plasmid-Encoded AmpC (pAmpC) in Enterobacteriaceae: epidemiology of microorganisms and resistance markers. Rev Argent Microbiol 2012;44:182-6
28. Hombach M, Mouttet B, Bloemberg GV. Consequences of revised CLSI and EUCAST guidelines for antibiotic susceptibility patterns of ESBL-and AmpC b-lactamase-producing clinical Enterobacteriaceae isolates. J Antimicrob Chemother 2013;68:2092-8
29. Chow JW, Fine MJ, Shlaes DM, et al. Enterobacter bacteremia: clinical features and emergence of antibiotic resistance during therapy. Ann Intern Med 1991;115: 585-90
30. Palzkill T. Metallo-b-lactamase structure and function. Ann N Y Acad Sci 2013;1277:91-104
31. Jones RN, Flonta M, Gurler N, et al. Resistance surveillance program report for selected European nations (2011). Diagn Microbiol Infect Dis 2014;78:429-36
32. Tellado JM, Sen SS, Caloto MT, et al. Consequences of inappropriate initial empiric parenteral antibiotic therapy among patients with community-acquired intraabdominal infections in Spain. Scand J Infect Dis 2007;39:947-55
33. Augustin P, Dinh AT, Valin N, et al. Pseudomonas aeruginosa post-operative peritonitis: clinical features, risk factors, and prognosis. Surg Infect (Larchmt) 2013;14: 297-303
34. Kumar A, Roberts D, Wood KE, et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med 2006;34:1589-96
35. Georges B, Conil JM, Dubouix A, et al. Risk of emergence of Pseudomonas aeruginosa resistance to beta-lactam antibiotics in intensive care units. Crit Care Med 2006;34:1636-41
36. Bonomo RA, Szabo D. Mechanisms of multidrug resistance in Acinetobacter species and Pseudomonas aeruginosa. Clin Infect Dis 2006;43(Suppl 2):S49-56
37. Livermore DM. Has the era of untreatable infections arrived? J Antimicrob Chemother 2009;64(Suppl 1):i29-36
38. Souli M, Galani I, Giamarellou H. Emergence of extensively drug-resistant and pandrug-resistant Gram-negative bacilli in Europe. Euro Surveill 2008;13:19045
39. Riera E, Cabot G, Mulet X, et al. Pseudomonas aeruginosa carbapenem resistance mechanisms in Spain: impact on the activity of imipenem, meropenem and doripenem. J Antimicrob Chemother 2011;66:2022-7
40. Edelsberg J, Berger A, Schell S, et al. Economic consequences of failure of initial antibiotic therapy in hospitalized adults with complicated intra-abdominal infections. Surg Infect (Larchmt) 2008;9:335-47
41. Shlaes DM. New b-lactam-b-lactamase inhibitor combinations in clinical development. Ann N Y Acad Sci 2013;1277:105-14
42. Hong MC, Hsu DI, Bounthavong M. Ceftolozane/tazobactam: a novel antipseudomonal cephalosporin and b-lactamase-inhibitor combination. Infect Drug Resist 2013;6:215-23
43. Livermore DM, Mushtaq S, Ge Y. Chequerboard titration of cephalosporin CXA-101 (FR264205) and tazobactam versus beta-lactamase-producing Enterobacteriaceae. J Antimicrob Chemother 2010;65:1972-4
44. Drawz SM, Bonomo RA. Three decades of beta-lactamase inhibitors. Clin Microbiol Rev 2010;23:160-201
45. Sader HS, Rhomberg PR, Farrell DJ, Jones RN. Antimicrobial activity of CXA-101, a novel cephalosporin tested in combination with tazobactam against Enterobacteriaceae, Pseudomonas aeruginosa, and Bacteroides fragilis strains having various resistance phenotypes. Antimicrob Agents Chemother 2011;55:2390-4
46. Zhanel GG, Chung P, Adam H, et al. Ceftolozane/tazobactam: a novel cephalosporin/b-lactamase inhibitor combination with activity against multidrug-resistant Gram-negative bacilli. Drugs 2014;74:31-51
47. Moyá B, Zamorano L, Juan C, et al. Affinity of the new cephalosporin CXA-101 to penicillin-binding proteins of Pseudomonas aeruginosa. Antimicrob Agents Chemother 2010;54:3933-7
48. Moyá B, Dötsch A, Juan C, et al. Beta-lactam resistance response triggered by inactivation of a nonessential penicillin-binding protein. PLoS Pathog 2009;5:e1000353
49. Melhem M, Forrest A, Rubino C, et al. Pharmacokinetic-pharmacodynamic (PKPD) target attainment (TA) analyses supporting the selection of in vitro susceptibility test interpretive criteria for ceftolozane/tazobactam (TOL/TAZ) against Pseudomonas aeruginosa. Abstracts of the 24th European Congress of Clinical Microbiology and Infectious Diseases; Barcelona, Spain; 2014. P1743
50. Hershberger E, Mouksassi M, Steenbergen J, et al. Pharmacokinetic (PK)/Pharmacodynamic (PD) target attainment (TA) using different dosing strategies for CXA-201 (CXA 101 in combination with tazobactum (TAZ) against difficult to treat Gram-negative Pathogens. Abstracts of the 21st European Congress of Clinical Microbiology and Infectious Diseases; Milan, Italy; 2011. P1520
51. Snydman DR, McDermott LA, Jacobus NV. Activity of ceftolozane-tazobactam against a broad spectrum of recent clinical anaerobic isolates. Antimicrob Agents Chemother 2014;58:1218-23
52. Farrell DJ, Sader HS, Castanheira M, Jones RN. Antimicrobial activity of ceftolozane/tazobactam and comparator agents tested against Enterobacteriaceae isolates from 14 European countries and Israel (2012). Abstracts of the 24th European Congress of Clinical Microbiology and Infectious Diseases; Barcelona, Spain; 2014. eP442
53. Farrell DJ, Flamm RK, Sader HS, Jones RN. Antimicrobial activity of ceftolozane-tazobactam tested against Enterobacteriaceae and Pseudomonas aeruginosa with various resistance patterns isolated in U.S. Hospitals (2011-2012). Antimicrob Agents Chemother 2013;57: 6305-10
54. Farrell DJ, Sader HS, Flamm RK, Jones RN. Ceftolozane/tazobactam activity tested against Gram-negative bacterial isolates from hospitalised patients with pneumonia in US and European medical centres (2012). Int J Antimicrob Agents 2014;43:533-9
55. Sader HS, Farrell DJ, Castanheira M, et al. Antimicrobial activity of ceftolozane/tazobactam tested against Pseudomonas aeruginosa and Enterobacteriaceae with various resistance patterns isolated in European hospitals (2011-12). J Antimicrob Chemother 2014. [Epub ahead of print]
56. Magiorakos AP, Srinivasan A, Carey RB, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect 2012;18:268-81
57. Sader HS, Farrell DJ, Flamm RK, Jones RN. Ceftolozane/tazobactam activity tested against aerobic Gram-negative organisms isolated from intra-abdominal and urinary tract infections in European and United States hospitals (2012). J Infect 2014. [Epub ahead of print]
58. McCurdy S, Petersen PJ, Steenbergen J, et al. Ceftolozane/tazobactam activity against Gram-negative bacteria causing intraabdmonial infections in European hospitals (2011-2012): a report from an International antimicrobial surveillance program. Abstracts of the 24th European Congress of Clinical Microbiology and Infectious Diseases; Barcelona, Spain; 2014. eP446
59. McCurdy S, Petersen PJ, Steenbergen J, et al. Ceftolozane/tazobactam activity against Gram-negative bacteria causing urinary tract infections in European hospitals (2011-2012): a report from an International antimicrobial surveillance program. Abstracts of the 24th European Congress of Clinical Microbiology and Infectious Diseases; Barcelona, Spain; 2014. eP445
60. Farrell DJ, Sader HS, Flamm RK, Jones RN. Ceftolozane/tazobactam activity when tested against Gram-negative bacteria isolates from hospitalized patients with pneumonia in European hospitals (2011-2012). Abstracts of the 24th European Congress of Clinical Microbiology and Infectious Diseases; Barcelona, Spain; 2014. eP443
61. Titelman E, Karlsson IM, Ge Y, Giske CG. In vitro activity of CXA-101 plus tazobactam (CXA-201) against CTX-M-14-and CTX-M-15-producing Escherichia coli and Klebsiella pneumoniae. Diagn Microbiol Infect Dis 2011;70:137-41
62. Garc?á-Castillo M, Tato M, Bou G, et al. Comparative in vitro activity of ceftolozane/tazobactam against clinical isolates of Enterobacteriaceae: results of the CENIT multi-centre study. Abstracts of the 24th European Congress of Clinical Microbiology and Infectious Diseases; Barcelona, Spain; 2014. eP447
63. Cabot G, Bruchmann S, Mulet X, et al. Pseudomonas aeruginosa ceftolozane-tazobactam resistance development requires multiple mutations leading to overexpression and structural modification of AmpC. Antimicrob Agents Chemother 2014;58:3091-9
64. Moyá B, Beceiro A, Cabot G, et al. Pan-b-lactam resistance development in Pseudomonas aeruginosa clinical strains: molecular mechanisms, penicillin-binding protein profiles, and binding affinities. Antimicrob Agents Chemother 2012;56: 4771-8
65. Riera E, Macià MD, Mena A, et al. Anti-biofilm and resistance suppression activities of CXA-101 against chronic respiratory infection phenotypes of Pseudomonas aeruginosa strain PAO1. J Antimicrob Chemother 2010;65:1399-404
66. Takeda S, Nakai T, Wakai Y, et al. In vitro and in vivo activities of a new cephalosporin, FR264205, against Pseudomonas aeruginosa. Antimicrob Agents Chemother 2007;51:826-30
67. Walkty A, Karlowsky JA, Adam H, et al. In vitro activity of ceftolozane-tazobactam against Pseudomonas aeruginosa isolates obtained from patients in Canadian hospitals in the CANWARD study, 2007 to 2012. Antimicrob Agents Chemother 2013;57:5707-9
68. Tato M, Garc?á-Castillo M, Moreno-Bofarull A, et al. Comparative in vitro activity of ceftolozane/tazobactam against clinical isolates of Pseudomonas aeruginosa: results of the CENIT multi-centre study. Abstracts of the 24th European Congress of Clinical Microbiology and Infectious Diseases; Barcelona, Spain; 2014. eP448
69. Farrell DJ, Sader HS, Castanheira M, Jones RN. Antimicrobial activity of ceftolozane/tazobactam and comparator agents tested against Pseudomonas aeruginosa isolates from 15 European countries and Israel (2011-2012). Abstracts of the 24th European Congress of Clinical Microbiology and Infectious Diseases; Barcelona, Spain; 2014. eP444
70. Bulik CC, Christensen H, Nicolau DP. In vitro potency of CXA-101, a novel cephalosporin, against Pseudomonas aeruginosa displaying various resistance phenotypes, including multidrug resistance. Antimicrob Agents Chemother 2010;54:557-9
71. Zamorano L, Juan C, Fernández-Olmos A, et al. Activity of the new cephalosporin CXA-101 (FR264205) against Pseudomonas aeruginosa isolates from chronically-infected cystic fibrosis patients. Clin Microbiol Infect 2010;16:1482-7
72. Moyá B, Zamorano L, Juan C, et al. Activity of a new cephalosporin, CXA-101 (FR264205), against beta-lactam-resistant Pseudomonas aeruginosa mutants selected in vitro and after antipseudomonal treatment of intensive care unit patients. Antimicrob Agents Chemother 2010;54: 1213-17
73. Juan C, Zamorano L, Pérez JL, Spanish Group for the Study of Pseudomonas; Spanish Network for Research in Infectious Diseases. Activity of a new antipseudomonal cephalosporin, CXA-101 (FR264205), against carbapenem-resistant and multidrug-resistant Pseudomonas aeruginosa clinical strains. Antimicrob Agents Chemother 2010;54:846-51
74. Livermore DM, Mushtaq S, Ge Y, Warner M. Activity of cephalosporin CXA-101 (FR264205) against Pseudomonas aeruginosa and Burkholderia cepacia group strains and isolates. Int J Antimicrob Agents 2009;34:402-6
75. Riera E, Macià MD, Mena A, et al. Anti-biofilm and resistance suppression activities of CXA-101 against chronic respiratory infection phenotypes of Pseudomonas aeruginosa strain PAO1. J Antimicrob Chemother 2010;65:1399-404
76. Soon RL, Forrest A, Holden PN, et al. In vitro pharmacodynamics of CXA-2001 (ceftolozane/tazobactam) against b-lactamase producing Escherichia coli. Abstracts of the 52nd Annual Interscience Conference on Antimicrobial Agents and Chemotherapy; San Francisco, CA, USA; 2012. E-201
77. Brown NP, Pillar CM, Draghi DC, et al. Mode of action of CXA-101 based on minimum bactericidal concentration analysis and time-kill kinetic analysis. Abstracts of the 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy & the Infectious Disease Society of America 46th Annual Meeting; Washington DC, USA; 2008. F1-358
78. Sader HS, Rhomberg PR, Jones RN. Postb-lactamase-inhibitor effect of tazobactam in combination with ceftolozane on extendedspectrum-b-lactamase-producing strains. Antimicrob Agents Chemother 2014;58: 2434-7
79. CraigWA, Andes DR. In vivo activities of ceftolozane, a new cephalosporin, with and without tazobactam against Pseudomonas aeruginosa and Enterobacteriaceae, including strains with extended-spectrum b-lactamases, in the thighs of neutropenic mice. Antimicrob Agents Chemother 2013;57:1577-82
80. Andes D, Alex L. In vivo pharmacodynamics of ceftolozane against Streptococcus pneumoniae and Pseudomonas aeruginosa across a wide range of MICs in a neutropenic murine thigh infection model. Abstracts of the 24th European Congress of Clinical Microbiology and Infectious Diseases; Barcelona, Spain; 2014. P1735
81. Jacqueline C, Roquilly A, Desessard C, et al. Efficacy of ceftolozane in a murine model of Pseudomonas aeruginosa acute pneumonia: in vivo antimicrobial activity and impact on host inflammatory response. J Antimicrob Chemother 2013;68:177-83
82. Jacqueline C, Desessard C, Roquilly A, et al. 50% Effective dose (ED50) determination of CXA-101 (CXA) alone or in combination with tazobactam (TAZ) for treating experimental peritonitis in mice due to extended-spectrum blactamase (ESBL)-producing Escherichia coli (EC) strains: Comparison with ceftazidime (CAZ) and piperacillin/tazobactam (TZP). Abstracts of the 49th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy; San Francisco, CA, USA; 2009. F1-2000
83. Jacqueline C, Desessard C, Amador G, et al. ED50 determination of CXA-101 alone and in combination with tazobactam (TAZ) for treating experimental peritonitis in mice due to ESBL-producing Klebsiella pneumoniae (KP) strains: Comparison with ceftazidime (CAZ) and piperacillin/tazobactam (TZP). Abstracts of the 50th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy; Boston, MA, USA; 2010. B-708
84. Bulik CC, Tessier PR, Keel RA, et al. In vivo comparison of CXA-101 (FR264205) with and without tazobactam versus piperacillin-tazobactam using human simulated exposures against phenotypically diverse Gram-negative organisms. Antimicrob Agents Chemother 2012;56:544-9
85. Vanscoy B, Mendes RE, Castanheira M, et al. Relationship between ceftolozane-tazobactam exposure and drug resistance amplification in a hollow-fiber infection model. Antimicrob Agents Chemother 2013;57:4134-8
86. Ge Y, Whitehouse MJ, Friedland I, Talbot GH. Pharmacokinetics and safety of CXA-101, a new antipseudomonal cephalosporin, in healthy adult male and female subjects receiving single-and multiple-dose intravenous infusions. Antimicrob Agents Chemother 2010;54: 3427-31
87. Miller B, Hershberger E, Benziger D, et al. Pharmacokinetics and safety of intravenous ceftolozane-tazobactam in healthy adult subjects following single and multiple ascending doses. Antimicrob Agents Chemother 2012;56:3086-91
88. Chandorkar G, Huntington JA, GotfriedMH, et al. Intrapulmonary penetration of ceftolozane/tazobactam and piperacillin/tazobactam in healthy adult subjects. J Antimicrob Chemother 2012;67:2463-9
89. Wooley M, Miller B, Krishna G, et al. Impact of renal function on the pharmacokinetics and safety of ceftolozane-tazobactam. Antimicrob Agents Chemother 2014;58:2249-55
90. Wooley M, Bernardo P, Miller B, et al. Evaluation of the potential for drug-drug interactions between ceftolozane/tazobactam and drugs metabolised by CYP1A2 or CYP3A4 or transported by OAT1 and OAT3. Abstracts of the 24th European Congress of Clinical Microbiology and Infectious Diseases; Barcelona, Spain; 2014. eP450
91. Wise R, Logan M, Cooper M, Andrews JM. Pharmacokinetics and tissue penetration of tazobactam administered alone and with piperacillin. Antimicrob Agents Chemother 1991;35:1081-4
92. Wagenlehner F, Umeh O, Huntington J, et al. Efficacy and safety of ceftolozane/tazobactam versus levofloxacin in the treatment of complicated urinary tract infections (cUTI)/pyelonephritis in hospitalised adults: results from the phase 3 aspect-cUTI trial. Abstracts of the 24th European Congress of Clinical Microbiology and Infectious Diseases; Barcelona, Spain; 2014. eP449
93. Lucasti C, Hershberger E, Miller B, et al. A Multicenter, double-blind, randomized, Phase 2 study to assess the safety and efficacy of ceftolozane/tazobactam (TOL/TAZ) plus metronidazole (MTZ) compared to meropenem (MER) in adult patients with complicated intra-abdominal infections (cIAI). Abstracts of the 53rd Annual Interscience Conference on Antimicrobial Agents and Chemotherapy; Denver, CO, USA; 2013. K1709
94. Eckmann C, Hershberger E, Miller B, et al. Efficacy and safety of ceftolozane/tazobactam versus meropenem in the treatment of complicated intra-abdominal infections (cIAI) in hospitalised adults: results from the phase 3 aspect-cIAI trial. Abstracts of the 24th European Congress of Clinical Microbiology and Infectious Diseases; Barcelona, Spain; 2014. eP0266a
95. Gram-negative: ceftolozane/tazobactam. Available from: www.cubist.com/products/ceftolozane-tazobactam